GlassScriptPhysician profile
Jacob Mk New
NPI 1740800325
$2,502.69
in general payments reported to CMS, 2019-2025
31 companies · $772 in 2025
The $772 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.63 · 2023: $491 · 2024: $1,225 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,488.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $392.92 | 2024-2025 | Opdivo |
| Gilead Sciences, INC. | $296.18 | 2023-2025 | Trodelvy |
| Abbvie INC. | $175.48 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.99 | 2024-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Eisai INC. | $139.26 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $130.88 | 2023-2025 | Keytruda, Lynparza |
| Amgen INC. | $126.10 | 2023 | Lumakras, Vectibix, Xgeva |
| Pharmaessentia USA Corporation | $97.95 | 2024 | Besremi |
| Pfizer INC. | $96.55 | 2024-2025 | |
| Kite Pharma, INC. | $78.82 | 2024-2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $71.37 | 2024-2025 | Imfinzi |
| Glaxosmithkline, LLC. | $64.66 | 2024 | Ojjaara |
| Deciphera Pharmaceuticals INC. | $57.43 | 2023-2024 | Qinlock |
| Stemline Therapeutics INC. | $55.00 | 2024 | Orserdu |
| Beigene USA, INC. | $53.04 | 2024 | Brukinsa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $51.21 | 2023 | Adcetris |
| Puma Biotechnology, INC. | $49.45 | 2024 | |
| Array Biopharma INC | $46.37 | 2023 | Braftovi, Lorbrena, Xalkori |
| Janssen Biotech, INC. | $45.62 | 2025 | Talvey, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $44.22 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.52 | 2024 | |
| Daiichi Sankyo INC. | $31.50 | 2023-2024 | Enhertu |
| Csl Behring | $31.00 | 2024 | Idelvion, Afstyla |
| Blueprint Medicines Corporation | $28.73 | 2024 | Ayvakit |
| Adc Therapeutics America, INC. | $28.61 | 2024 | |
| Astellas Pharma US INC | $24.02 | 2025 | Vyloy |
| Incyte Corporation | $21.96 | 2024 | Jakafi |
| Tersera Therapeutics LLC | $20.49 | 2025 | Zoladex |
| Tempus Ai, INC | $19.69 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.15 | 2025 | Libtayo |
| Sobi, INC | $12.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob New listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.